| Description | Ontuxizumab (MORAb-004) is a monoclonal antibody targeting endomelanic acid with anti-tumor effects.Ontuxizumab is a potent IgG1/κ anti-endothelin (TEM-1 or CD248) monoclonal antibody for the treatment of metastatic melanoma. |
| In vitro | Ontuxizumab能够以剂量依赖的方式诱导CD248内吞，经过12小时处理，其浓度范围从0至100 μg/mL时，人类真皮成纤维细胞表面CD248降低了46%[1]。 |
| In vivo | 在人类CD248敲入小鼠中，通过静脉注射给药，每天五次，连续五天，每次剂量为50 mg/kg时，Ontuxizumab显示出抗肿瘤效果[1]。 |
| Synonyms | MORAb-004 |
| molecular weight | N/A |
| CAS | 946415-62-9 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Rybinski K, et al. Targeting endosialin/CD248 through antibody-mediated internalization results in impaired pericyte maturation and dysfunctional tumor microvasculature. Oncotarget. 2015 Sep 22;6(28):25429-40. |